Company Monitoring Page for Sanofi

latest headlines for company on cafepharma

What Investors Can Learn from MannKind Corporation's Afrezza Fiasco
Motley Fool
Tue, 01/12/16 - 10:01 am
Tags:
MannKind, Afrezza, Sanofi
The Lesson Of MannKind Corporation
Seeking Alpha
Thu, 01/7/16 - 08:56 am
Tags:
MannKind, Sanofi, Afrezza, diabetes, inhaled insulin
MannKind Corp. Sinks Again On Bankruptcy Concerns
Motley Fool
Wed, 01/6/16 - 10:47 am
Tags:
MannKind, bankruptcy, Afrezza, Sanofi, inhaled insulin, diabetes
2 Reasons Behind MannKind Corporation's Implosion in 2015
Motley Fool
Tue, 01/5/16 - 09:17 pm
Tags:
MannKind, Afrezza, diabetes, Sanofi
MannKind Corporation Announces Termination of License and Collaboration Agreement With Sanofi
Yahoo
Tue, 01/5/16 - 09:33 am
Tags:
MannKind, Afrezza, Sanofi, diabetes, inhaled insulin
What Does 2016 Hold for Biotech Stocks?
Motley Fool
Sun, 01/3/16 - 10:27 pm
Tags:
biotech, Gilead Sciences, Celgene, Amgen, Regeneron, Sanofi, Biomarin, Sarepta Th
Is AstraZeneca a Better Suitor for Relypsa Than Sanofi?
Bidness, ETC
Mon, 12/28/15 - 10:03 am
Tags:
AstraZeneca, Relypsa, Sanofi, Merck, M&A
The biosimilars are coming. But how long will it be till they can make their mark?
Fierce Pharma
Sat, 12/26/15 - 08:49 pm
Tags:
biosimilars, Sanofi, Amgen, Eli Lilly
Sanofi takes an FDA shortcut with its diabetes combo, racing with Novo
Fierce Biotech
Wed, 12/23/15 - 09:34 pm
Tags:
Sanofi, Novo Nordisk, diabetes, FDA, Lantus, lixisenatide
11 biopharma execs & experts look back on 2015: A record year for record-breaking
BioPharma Dive
Wed, 12/23/15 - 09:32 pm
Tags:
Sanofi, Pfenex, inVentiv, Novocure, Accenture, Boehringer Ingelheim
Relypsa Gets More Attractive For Merck, Sanofi
Bidness, ETC
Wed, 12/23/15 - 09:26 pm
Tags:
Relypsa, Merck, Sanofi, M&A
Sanofi Gains on New Drug Application
Bidness, ETC
Wed, 12/23/15 - 11:13 am
Tags:
Sanofi, diabetes, insulin glargine, lixisenatide
The Right Drug For Big Pharma: Precision M&A
Seeking Alpha
Tue, 12/22/15 - 10:55 am
Tags:
M&A, AstraZeneca, GSK, JNJ, Novartis, Sanofi
Amgen PCSK-9 Prescription Volumes Ahead of Regeneron Pharmaceuticals
Bidness, ETC
Fri, 12/18/15 - 09:09 am
Tags:
Amgen, PCSK9 inhibitors, Regeneron, Sanofi, Repatha, Praluent
Lilly gets its Lantus copycat Basaglar approved by FDA—but not as a biosimilar
BioPharma Dive
Thu, 12/17/15 - 02:00 pm
Tags:
diabetes, Eli Lilly, Lantus, Basaglar, insulin, FDA, biosimilars, Sanofi
Sanofi's poised for No. 1 in consumer health, but Bayer plans to fight back with M&A
Fierce Pharma
Wed, 12/16/15 - 08:01 pm
Tags:
Sanofi, consumer health, Bayer, M&A
FDA approves cheaper version of top-selling diabetes drug
Yahoo/Reuters
Wed, 12/16/15 - 07:56 pm
Tags:
FDA, diabetes, insulin, Lantus, Eli Lilly, Boehringer Ingelheim, Sanofi
Sanofi plans to reshape via $20 bln asset swap with Boehringer
Yahoo/Reuters
Tue, 12/15/15 - 09:58 am
Tags:
Sanofi, Boehringer Ingelheim
Latest cholesterol drug comes with a $14,600-a-year price tag
Marketwatch
Mon, 12/14/15 - 04:27 pm
Tags:
cholesterol, Praluent, Regeneron, Sanofi
The new PCSK9 scorecard: Praluent favored by UnitedHealth, Repatha by CVS, both by Express Scripts
BioPharma Dive
Fri, 12/11/15 - 10:23 pm
Tags:
PCSK9 inhibitors, Praluent, Repatha, Regeneron, Sanofi, Amgen, Unitedhealth Group, CVS, Express Scripts

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.